Skip to main content

CORRECTION article

Front. Immunol., 12 January 2022
Sec. Vaccines and Molecular Therapeutics
Volume 12 - 2021 | https://doi.org/10.3389/fimmu.2021.815812

Corrigendum: Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inflammation and Blood Inflammatory Biomarkers in Mild to Moderate COVID-19 Patients: A Pilot Study

This article is a correction to:

  1. Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inflammation and Blood Inflammatory Biomarkers in Mild to Moderate COVID-19 Patients: A Pilot Study

    1. Read original article
Thais G. MoreiraThais G. Moreira1Kimble T. F. MatosKimble T. F. Matos2Giovana S. De PaulaGiovana S. De Paula3Thais M. M. SantanaThais M. M. Santana3Raquel G. Da MataRaquel G. Da Mata3Fernando C. PanseraFernando C. Pansera3Andre S. CortinaAndre S. Cortina3Marcelle G. SpinolaMarcelle G. Spinola2Clare M. Baecher-AllanClare M. Baecher-Allan1Gerson D. KeppekeGerson D. Keppeke2Jules JacobJules Jacob4Vaseem PalejwalaVaseem Palejwala4Karen ChenKaren Chen5Saef IzzySaef Izzy1Brian C. HealeyBrian C. Healey1Rafael M. RezendeRafael M. Rezende1Rogerio A. DedivitisRogerio A. Dedivitis3Kunwar ShailubhaiKunwar Shailubhai4Howard L. Weiner*Howard L. Weiner1*
  • 1Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, United States
  • 2Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil
  • 3Santa Casa de Misericordia de Santos, Santos, Brazil
  • 4Tiziana LifeScience, Doylestown, PA, United States
  • 5Department of Radiology, Boston Children’s Hospital, Harvard Medical School, Boston, MA, United States

A Corrigendum on:
Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inflammation and Blood Inflammatory Biomarkers in Mild to Moderate COVID-19 Patients: A Pilot Study

By Moreira TG, Matos KTF, De Paula GS, Santana TMM, Da Mata RG, Pansera FC, Cortina AS, Spinola MG, Baecher-Allan CM, Keppeke GD, Jacob J, Palejwala V, Chen K, Izzy S, Healey BC, Rezende RM, Dedivitis RA, Shailubhai K and Weiner HL (2021). Front. Immunol. 12:709861. doi: 10.3389/fimmu.2021.709861

Clare M. Baecher-Allan was not included as an author in the published article. The corrected Author Contributions Statement appears below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

“TM designed the study, led and monitored this clinical study, and wrote the manuscript. KM designed the study, clinically monitored the study, and performed Lung CT analysis. GD and TS recruited patients, performed clinical exams, registered drug intake and medical past history. RGD, monitored the study and helped collect BMI data. FP and AC supported patient recruitment. MS performed biomarkers assays. CMB-A participated in drug development. GK performed serum and plasma collection. JJ and VP performed drug stability assays. SI and KC performed Lung CT scan analysis. BH performed statistical analysis. RR designed the study and reviewed manuscript. RAD helped supervise the study at Santa Casa de Santos Hospital. KS helped design the study and reviewed the manuscript. HW designed the study and helped write the manuscript. All authors contributed to the article and approved the submitted version.”

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: foralumab, anti-CD3, COVID-19, SARS-CoV-2, immune responses

Citation: Moreira TG, Matos KTF, De Paula GS, Santana TMM, Da Mata RG, Pansera FC, Cortina AS, Spinola MG, Baecher-Allan CM, Keppeke GD, Jacob J, Palejwala V, Chen K, Izzy S, Healey BC, Rezende RM, Dedivitis RA, Shailubhai K and Weiner HL (2022) Corrigendum: Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inflammation and Blood Inflammatory Biomarkers in Mild to Moderate COVID-19 Patients: A Pilot Study. Front. Immunol. 12:815812. doi: 10.3389/fimmu.2021.815812

Received: 15 November 2021; Accepted: 23 December 2021;
Published: 12 January 2022.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2022 Moreira, Matos, De Paula, Santana, Da Mata, Pansera, Cortina, Spinola, Baecher-Allan, Keppeke, Jacob, Palejwala, Chen, Izzy, Healey, Rezende, Dedivitis, Shailubhai and Weiner. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Howard L. Weiner, aHdlaW5lckByaWNzLmJ3aC5oYXJ2YXJkLmVkdQ==

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.